MBBS.,MD (Rad Onc)., DNB., DM (MedOnc)., MSc (Onc and Pall care UK)
Area(s) of Specialization:
Moday to Saturday
Tuesday: 8.30 a.m - 4 p.m
Monday Saturday: 2 p.m - 4 p.m
For Appointment, Call:
044-45928500 EXT: 316/3410
Fellowships / Memberships:
Fellowship in Intensive Care Medicine
Member of Indian Medical Council RC num 72678
Member of Association of Radiation Oncology of India (AROI)
Fellow of Council of Independent Physicians of India
American Society of Clinical Oncology- Membership Number : 90829
Indian Association of Palliative Care –Ref num LF/P/61
Indian Medical Association Academy of Medical Specialties- TN /616/11/13/2009-2010/L
Indian Brachytherapy Society-LM 158
Canadian Association of Radiation Oncology-Ref num 10001529
American Society of Radiation Oncology- Member Number 35242395
European Society of Medical Oncology number 81383
Prescribing Pattern of Anticancer Drugs in a Medical Oncology Department of a Tertiary Care Teaching Hospital Manichavasagam M, P Jovita M Martin, Lavanya R, Karthik S, Seenivasan P and Rajanandh MG* Annals of Medical and Health Sciences Research July 25th 2017
Prevalence Of Androgen Receptor Positivity In Triple Negative Breast Cancer Martin P Jovita M*, Kalaichelvi Kannan and Kumar S Suresh Martin et al., J Integr Oncol 2018, 7:1
An Uneventful Pregnancy and Delivery in a Metastatic Adult Wilms’ Tumor–A Rare Case Report MOJ Clinical and Medical case Reports Volume 7 Issue 4 2017.
Multiple Primaries Rising Trend– a Case Series. P.Jovita M.Martin, Vijayasarathy.K.International journal of /medical Sciences and Health Research. Vol.01,Number 01,;2017 ISSN: 2581-3366
Primary Intraspinal Primitive Neuro ectodermal tumor (PNET): A Rare Occurrence. Martin J (2017) MOJ Clin Med CASE Rep 7 (5): 00214
Androgen receptor positivity in triple-negative breast cancer.P. Jovita M. Martin, Kalaichelvi K, Suresh Kumar. Journal of Evolution of Medical and Dental sciences. September, Vol 7,Issue 36 Page 3959-396
A 20 years’ experience on granulosa cell tumour. .P. Jovita M. Martin, Kalaichelvi K, Lakshminarasimhan, Ramkumar, Dheenadhayalan. Journal of Evolution of Medical and Dental sciences 2018;7(26):3004-3012
Clinical Research Experience (at Sri Ramachandra Medical College and Hospital, Chennai)
Trial Team In charge on Combined Modality Treatment Cancer Esophagus Reference based on INT0123 and RTOG 94-05 Phase III.
Sub-Investigator -A multinational randomized ,double blinded , placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) incancer patients at high risk for VTE and who are undergoing chemotherapy 2008 to 2010.
Co-Investigator- A prospective ,non comparative ,open labeled,multicenter Post Marketing Safety Surveillance study to evaluate the safety and immunogenicity of neukine in clinical practice 2008 to 2009.
Co-Investigator-A phase I/II study to evaluate safety and efficacy of P276-00 in combination with Gemcitabine in patients with cancer of pancreas .
Co-Investigator-A phase III open label extension trial of the safety and efficacy of ferumoxytol for episodic treatment of Iron deficiency anaemia.
Co-Investigator- Predictive factors in Stomach Cancers Evaluation of Polymorphisms in Thymidilate synthase gene as markers for response to 5-Fluorouracil based treatment regimen in Gastric Cancer in an Indian Population (awaiting sanction for funding ICMR)
Principle Investigator: Protocol No: GBR 200-301 ‘’A Prospective , Multicentre , Randomized , Double – blind , Parallel- Group study to compare the efficacy and safety of GBR 200 (similar biologic of trastuzumab ) versus innovator trastuzumab both given in combination with paclitaxel in patients diagnosed with HER2 positive Metastatic breast cancer .
Principle Investigator: BCD-021-02 ‘’ International multicentre randomized double blind phase III trial comparing safet) and efficacy of BCD-021 (CJSC BIOCAD, Russia ) and paclitaxel + carboplatin to Avastin ( F. Hoffmann – La Roche LTD , Switzerland ) and paclitaxel + carboplatin in inoperable or advanced non- squamous non- small – cell lung cancer patients. ‘’
Principle Investigator A Randomised open labelled two arm, single dose, cross over, bioequilence study of Ayana pharma Doxorubicin Hydrochloride Liposome injection , Sun pharma in subjects with ovarian cancer
Dr. P. Jovita M. Martin delivered a guest lecture on “Cancer Awareness” at ASCENDAS, IT Park to the AMEC Foster wheeler on 22 nd March 2018 at attended one day workshop on “Electro-Chemo Therapy for Effective Cancer Treatment” held on 14 th March 2018 at BS Abdur Rahman Crescent Institute of Science and Technology, Vandalur, Chennai.
Dr. Jovita Martin as Speaker at Mumbai in Best of MASCC on September 1 st 2018 Topic Oncological Emergencies in Palliative care.
Dr. Jovita Martin as Panelist in Multiple Myeloma at Madurai 10 th November 2018
Dr.Jovita Martin as speaker at Chicago 27 th World Oncologists Conference.Topic .A 20 years’ experience on granulosa cell tumour on Dec 7 th 2018.